Milestone Pharmaceuticals Inc. (MIST) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $384.99M; Additional Paid in CapitalUSD $62.87M; Retained Earnings (Accumulated Deficit)USD $-485.28M; Stockholders' Equity Attributable to ParentUSD $18.22M.
- 2026-03-31: Common Stock, Value, IssuedUSD $373.70M; Additional Paid in CapitalUSD $63.37M; Retained Earnings (Accumulated Deficit)USD $-456.67M; Stockholders' Equity Attributable to ParentUSD $36.05M.
- 2025-12-31: Common Stock, Value, IssuedUSD $352.62M; Additional Paid in CapitalUSD $64.10M; Retained Earnings (Accumulated Deficit)USD $-430.60M; Stockholders' Equity Attributable to ParentUSD $41.77M.
- 2025-09-30: Common Stock, Value, IssuedUSD $311.78M; Additional Paid in CapitalUSD $66.27M; Retained Earnings (Accumulated Deficit)USD $-413.19M; Stockholders' Equity Attributable to ParentUSD $20.50M.
Milestone Pharmaceuticals Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Recognition and Exercise USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $384.99M | $62.87M | $-485.28M | $18.22M | 3 month · $1.34M 6 month · $2.62M | (m) | (m) | (m) |
| 2026-03-31 | $373.70M | $63.37M | $-456.67M | $36.05M | 3 month · $1.28M | (m) | (m) | (m) |
| 2025-12-31 | $352.62M | $64.10M | $-430.60M | $41.77M | 12 month · $7.46M | (m) | (m) | (m) |
| 2025-09-30 | $311.78M | $66.27M | $-413.19M | $20.50M | 3 month · $1.25M 9 month · $3.91M | (m) | (m) | (m) |
| 2025-06-30 | $288.26M | $42.19M | $-401.27M | $-17.75M | 3 month · $1.31M 6 month · $2.66M | (m) | (m) | (m) |
| 2025-03-31 | $288.19M | $40.92M | $-388.31M | $-6.12M | 3 month · $1.35M | (m) | (m) | (m) |
| 2024-12-31 | $288.05M | $39.57M | $-367.55M | $13.15M | 12 month · $5.78M | (m) | (m) | (m) |
| 2024-09-30 | $288.01M | $38.11M | $-355.18M | $24.01M | 3 month · $1.40M 9 month · $4.30M | (m) | (m) | (m) |
| 2024-06-30 | $287.93M | $36.71M | $-345.74M | $31.98M | 3 month · $1.39M 6 month · $2.90M | (m) | (m) | (m) |
| 2024-03-31 | $287.88M | $35.35M | $-336.38M | $39.92M | 3 month · $1.51M | (m) | (m) | (m) |
| 2023-12-31 | $260.50M | $33.83M | $-326.03M | $16.77M | 12 month · $9.53M | (m) | (m) | (m) |
| 2023-09-30 | $260.50M | $31.96M | $-312.42M | $28.50M | 3 month · $2.87M 9 month · $7.66M | (m) | (m) | (m) |
| 2023-06-30 | $260.17M | $29.11M | $-297.33M | $40.41M | 3 month · $2.49M 6 month · $4.79M | (m) | (m) | (m) |
| 2023-03-31 | $260.13M | $26.64M | $-281.29M | $53.94M | 3 month · $2.29M | (m) | (m) | (m) |
| 2022-12-31 | $273.90M | $24.44M | $-266.34M | $66.35M | 12 month · $9.05M | (m) | (m) | (m) |
| 2022-09-30 | $254.94M | $22.44M | $-251.53M | $77.16M | 3 month · $2.38M 9 month · $6.91M | $-1.63M | (m) | (m) |
| 2022-06-30 | $252.24M | $20.09M | $-236.97M | $86.66M | 3 month · $2.41M 6 month · $4.53M | $-1.63M | (m) | (m) |
| 2022-03-31 | $251.99M | $17.79M | $-220.33M | $100.76M | 3 month · $2.11M | $-1.63M | (m) | (m) |
| 2021-12-31 | $251.90M | $15.71M | $-207.95M | $112.60M | 12 month · $7.28M | $-1.63M | (m) | (m) |
| 2021-09-30 | $251.77M | $13.79M | $-189.44M | $127.42M | 3 month · $2.02M 9 month · $5.30M | $-1.63M | (m) | (m) |
| 2021-06-30 | $251.72M | $11.79M | $-175.21M | $139.59M | 3 month · $1.91M 6 month · $3.28M | $-1.63M | (m) | (m) |
| 2021-03-31 | $251.72M | $9.88M | $-175.98M | $131.99M | 3 month · $1.37M | $-1.63M | (m) | 3 month · $-15.00K |
| 2020-12-31 | $251.68M | $8.53M | $-163.47M | $143.12M | 12 month · $4.95M | $-1.63M | (m) | (m) |
| 2020-09-30 | $226.76M | $7.10M | $-154.80M | $102.20M | 3 month · $1.34M 9 month · $3.52M | $-1.63M | (m) | 9 month · $-216.00K |
| 2020-06-30 | $226.68M | $5.79M | $-142.82M | $88.02M | 3 month · $1.19M | $-1.63M | (m) | 6 month · $-126.00K |
| 2020-03-31 | $226.38M | $4.73M | $-129.84M | $99.63M | 3 month · $981.00K | $-1.63M | (m) | 3 month · $-56.00K |
| 2019-12-31 | $226.25M | $3.81M | $-113.50M | $114.92M | 12 month · $1.19M | $-1.63M | $114.92M | 12 month · $41.00K |
| 2019-09-30 | $226.21M | $3.47M | $-95.21M | $132.83M | 3 month · $350.00K | $-1.63M | (m) | 9 month · $-26.00K |
| 2019-06-30 | $226.21M | $3.12M | $-82.38M | $145.31M | 3 month · $276.00K | $-1.63M | (m) | 6 month · $-26.00K |
| 2019-03-31 | $2.09M | $2.84M | $-68.72M | $73.33M | 3 month · $211.00K | $-1.63M | (m) | 3 month · $-26.00K |
| 2018-12-31 | $2.04M | $2.65M | $-58.27M | $83.55M | 12 month · $633.00K | $-1.63M | $-55.21M | 12 month · $350.00K |
| 2018-09-30 | (m) | (m) | (m) | (m) | 3 month · $85.00K | (m) | (m) | 9 month · $-32.00K |
| 2018-06-30 | (m) | (m) | (m) | (m) | 3 month · $79.00K | (m) | (m) | 6 month · $-32.00K |
| 2018-03-31 | (m) | (m) | (m) | (m) | 3 month · $125.00K | (m) | (m) | 3 month · $-25.00K |
| 2017-12-31 | (m) | (m) | (m) | $25.98M | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B |